Imaging Biomarkers of Knee Osteoarthritis
Study Details
Study Description
Brief Summary
This study aims to develop, evaluate and translate highly accelerated imaging sequences (each protocol under 5 minutes) for in-vivo knee Osteoarthritis applications on a standard clinical 3T scanner using novel compression sensing and parallel imaging strategies.The overarching objective of the study is to establish a non-invasive imaging biomarker based on the development of rapid relaxation mapping with compressed sensing (CS) that will be clinically useful for assessment of early Osteoarthritis. A total of 90 subjects including 30 patients with high risk of developing knee OA, 30 patients with mild OA and 30 healthy controls will be accrued.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Detailed Description
Current noninvasive imaging methods to evaluate knee joints include plain radiographs, computed tomography (CT), and clinical morphological magnetic resonance imaging (MRI) of joint structures. These techniques can only detect later-stage, macroscopic joint structural abnormalities that are irreversible and not amenable to early therapy. This study aims to develop highly accelerated imaging sequences for ex-vivo knee OA applications on a standard clinical 3T scanner using novel CS and parallel imaging (PI) strategies.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Active Comparator: High Risk for Osteoarthritis "High risk of developing knee OA" has been defined by having knee pain but normal radiographs (Kellgren-Lawrence score 0 i.e. KL0) on both knees but at least one abnormal finding on clinical MR protocol such as overweight, prior knee injury (ligaments or menisci) or traumatic bone marrow edema lesions. |
Device: PRISMA 3T MRI scanner (Siemens Medical Solutions)
A baseline MRI exam consisting of accelerated 3D-T1p, and T2, MRI will be performed. Longitudinal follow-up MRI exams (24 months) will be repeated on the same knee on all OA patients.
|
| Active Comparator: Mild Osteoarthritis
|
Device: PRISMA 3T MRI scanner (Siemens Medical Solutions)
A baseline MRI exam consisting of accelerated 3D-T1p, and T2, MRI will be performed. Longitudinal follow-up MRI exams (24 months) will be repeated on the same knee on all OA patients.
|
| Active Comparator: Healthy Controls Controls will be age/gender matched to patients within 2 years of age. |
Device: PRISMA 3T MRI scanner (Siemens Medical Solutions)
A baseline MRI exam consisting of accelerated 3D-T1p, and T2, MRI will be performed. Longitudinal follow-up MRI exams (24 months) will be repeated on the same knee on all OA patients.
|
Outcome Measures
Primary Outcome Measures
- Change in Cartilage Composition as Measured by 3D-T1p MRI Mapping [Baseline, Month 24]
MRI exam of accelerated 3D-T1p conducted on whole knee joint specimens to determine cartilage composition.
- Change in Cartilage Composition as Measured by T2 MRI Mapping [Baseline, Month 24]
MRI exam of accelerated T2 conducted on whole knee joint specimens to determine cartilage composition.
Secondary Outcome Measures
- Change in Western Ontario and McMaster University OA Index (WOMAC) [Baseline, Month 24]
The WOMAC is a 33-item self assessment of how participants feel about their knee and how well they can perform usual activities. The questionnaire contains 4 separately scored subscales - Symptoms; Stiffness; Pain; and Function, Daily Living. The total score is a percentage score from 0 to 100; lower scores represent less pain, less stiffness, and better physical function; higher scores indicate greater pain, greater stiffness, and worse physical function. A decrease in scores indicates participants' health improved during the observational period.
- Change in Knee Injury and OA Outcomes Score (KOOS) from Baseline [Baseline, Month 24]
Knee-specific instrument, developed to assess patients' opinion about their knee and associated problems. The KOOS evaluates both short-term and long-term consequences of knee injury. It holds 42 items in 5 separately scored subscales - Pain; Other Symptoms; Function in daily living (ADL); Function in Sport and Recreation (Sport/Rec); and knee-related Quality of Life (QOL). The total score is a percentage score from 0 to 100; 0 represents extreme problems and 100 represents no problems. An increase in scores indicates participants' health improved during the observational period.
- Change in Physical Activity Scale for the Elderly (PASE) Scores [Baseline, 24 Months]
Self-assessment of multiple domains of activity in older adults. Questions evaluate both occupational and non-occupational knee bending, squatting and stair climbing. Total scores range from 0 to 400 or above and are quantified based on frequency values and weights for these activities. Higher scores indicate higher levels of physical activity. An increase in scores indicates physical activity increased during the observational period.
Eligibility Criteria
Criteria
Inclusion Criteria:
- Patients in the HJD OA database, ages 40-75 with high risk of developing OA as defined by:
(i) KL score of 0 (ii) Knee pain present in at least 1 knee (iii) Normal radiographs, (iv) At least one abnormal clinical MR finding such as prior knee injury, overweight or traumatic bone marrow edema lesions
-
Patients ages 40-75 with early OA as determined by KL scores 1-2
-
Healthy controls in the HJD OA database (KL score 0, no knee pain, no meniscal or ligament tears)
Exclusion Criteria:
-
Contraindications for MRIs (e.g. pacemakers, ferromagnetic vascular clips, metal implants, claustrophobia, etc).
-
Subjects with any joint disease (example: Rheumatoid or inflammatory arthritis) other than knee OA, corticosteroid injections within the previous 3 months, and history of avascular necrosis, Paget's disease of bone, Wilson's disease, gout, total knee replacement (or plan for replacement within next 24 months).
-
Major co-morbidities such as diabetes, mellitus, cancer, congestive heart failure and chronic infectious diseases.
-
Alignment interventions such as insoles and knee braces
-
Vulnerable patients will not be recruited for this study
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | New York University School of Medicine | New York | New York | United States | 10016 |
Sponsors and Collaborators
- NYU Langone Health
- National Institutes of Health (NIH)
Investigators
- Principal Investigator: Ravinder Regatte, MD, New York University Medical School
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 16-00918